Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen

Urology

Volumn 48, Issue 6 SUPPL., 1996, Pages 10-15

  Semjonow, Axel ^a   Oberpenning, Frank ^a   Brandt, Burkhard ^a   Zechel, Christian ^a   Brandau, Wolfgang ^a   Hertle, Lothar ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD LEVEL; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 0030473107     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00604-8     Document Type: Article

References (24)

1. Littrup PJ, Goodman AC, Mettlin CJ, and Murphy GP: Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cost analyses of prostate cancer screening: frameworks for discussion. J Urol 152:1873-1877, 1994.
2. Allhoff E, de Riese W, Eifinger M, Pethke J, and Jonas U: Prostate-specific antigen - comparative clinical appreciation of a serodiagnostic measure after 8 years of experience. World J Urol 7: 12-16, 1989.
3. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, and Kidd DD: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143: 1146-1154, 1990.
4. Wirth MP, and Frohmüller HGW: Prostate-specific antigen and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases. Eur Urol 22: 27-32, 1992.
5. Hammerer P, Loy V, Dieringer J, and Huland H: Prostate cancer in nonurological patients with normal prostates on digital rectal examination. J Urol 147: 833-836, 1992.
6. Semjonow A, Brandt B, Oberpenning F, Roth S, and Hertle L: Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate, in press, 1996.
7. Semjonow A, Brandt B, Oberpenning F, and Hertle L: Unterschiedliche Bestimmungsverfahren erschweren die Interpretation des prostataspezifischen Antigens. Urologe A 34: 303-315, 1995.
8. Burlington DB: FDA advises labs regarding off-label use of PSA assays. Clin Lab News 21: 5, 1995.
9. Schambeck CM, Schmeller N, Stieber P, Jansen HM, Pahl H, Schneider W, and Fateh-Moghadam A: Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer. Urology 46: 195-199, 1995.
10. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, and Alfthan O: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
11. Bankson DD, Lyon ME, Costales LV, and Haver VM: The response of assays for total prostate specific antigen to changing proportions of "free" and alpha 1-antichymotrypsin bound PSA. Clin Chem 40: 1009, 1994.
12. Jacobsen SJ, Lilja H, Klee GG, Wright GL, Petterson K, and Oesterling JE: Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology 44: 512-518, 1994.
13. Drawer MK, Wener MH, Rittenhouse HG, and Wolfert RL: Proportion of free form of PSA explains the majority of bias between the IMx (Abbott) and Tandem (Hybritech) PSA assays. J Urol 155 (suppl): 416A, 1996.
14. Strobel S, Smith K, Wolfert R, and Rittenhouse H: Role of free PSA in discordance across commercial PSA assays. Clin Chem 42: 645-647, 1996.
15. Wang TJ, Hill T, Norton K, Sokoloff R, Frankenne F, Rittenhouse HG, and Wolfert RL: Specific immunoassay for free PSA and its clinical relevance. J Urol 153 (suppl): 295A, 1995.
16. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, and Larsen FL: Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 39: 2483-2491, 1993.
17. Graves HCB and Barren R: Progress towards PSA assay standards, in Cockett AK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (Eds): Proceedings of the 3rd International Consultation on BPH. Scientific Communication International, 1996, 404-419.
18. Graves HCB: Standardization of immunoassays for prostate-specific antigen. A problem of prostate-specific antigen complexation or a problem of assay design? Cancer 72: 3141-3144, 1993.
19. Graves HCB: Issues on standardization of immunoassays for prostate-specific antigen: A review. Clin Invest Med 16: 415-424, 1993.
20. Christensson A, Björk T, Nilsson O, Dahlen U, Matikainen M, Cockett ATK, Abrahamsson PA, and Lilja H: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
21. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, and Leinonen J: Serum concentrations of prostate specific antigen and its complex with alpha1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344: 1594-1598, 1994.
22. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
23. Partin AW, Kelly CA, Subong ENP, Walsh PC, Chan DW, Wang TJ, Rittenhouse HG, Wolfert RL, Norton KC, and McCormack R: Measurement of the ratio of free PSA to total PSA improves prostate cancer detection for men with total PSA levels between 4.0 and 10.0 ng/ml. J Urol 153 (suppl): 295A, 1995.
24. Brawer MK, Daum P, Petteway JC, and Wener MH: Assay variability in serum prostate-specific antigen determination. Prostate 27: 1-6, 1995.